Board of Directors and Management

      We are a skilled team of pharma and R&D professionals with extensive big pharma and biotech experience in drug discovery and development for several products now launched on the global market.

       

      Currently, the Board of Directors are only available in Swedish. If you need more information, please contact us.

      Board of Directors

      Daniel Johnsson

      Chairman of the board

      Born 1968. University studies at Chalmers University of Technology and the Gothenburg School of Business.

      Board member of Oblique Therapeutics Ab: Member since 2021
      Chairman of the Board: Quiq Holding Ab, Postery Ab, Krafthem Ab, Renable Ab, Admazing Ab
      Board member: Roscomar Ltd, Workpilots Oy
      Shareholding in Oblique Therapeutics Ab: 1,519,330 shares via company
      Main work experience: 25 years of experience as CEO of Exertis Nordics Ab, of which the last 7 years in a listed group. History as a serial entrepreneur with several successful exits. Today investor and advisor

      Marianne Dicander Alexandersson

      Member of the board

      Born 1959. Master of Science in Chemical Engineering, Chalmers University of Technology, Gothenburg.

      Board member of Oblique Therapeutics Ab: Member since 2021.
      Chairman of the Board: MDA Management Ab, Sahlgrenska Science Park Ab, Saminvest Ab, Occlutech Ab and the Royal Swedish Academy of Engineering Sciences (IVA West).
      Board member: Linc Ab, Promore Pharma Ab.
      Member: Dental and Pharmaceutical Benefits Agency (TLV) transparency council.
      Shareholding in Oblique Therapeutics Ab: no shares.
      Main work experience: Marianne was previously CEO of Kronans Droghandel Ab, Sjätte AP-fonden and Global Health Partner Ab and Deputy CEO of Apoteket Ab

      Lars Molinder

      Member of the board

      Born 1951. Master of Science in Engineering, Chalmers University of Technology, Gothenburg.

      Board member of Oblique Therapeutics Ab: Member since 2017
      Board member: Nordic Tender Ab
      Shareholding in Oblique Therapeutics Ab: no shares
      Main work experience: Lars has over 25 years of experience in investment banking in the Healthcare sector with a focus on biotechnology and pharmaceuticals. He has previously worked as sector manager in biotechnology and medicine at Industrifonden, sector manager for Healthcare at Alfred Berg / ABN AMRO and as sector manager for Healthcare at Carnegie Investment Bank. Since 2019, Lars has been associated with Carnegie Investment Bank as Senior Adviser within Healthcare. During his years in Investment Banking, he has been an advisor and responsible for a large number of IPOs and new issues as well as public and private M&A in the Nordic capital markets for Calliditas, Cellink, Camurus, Nuevolution, Oncopeptides, Medivir, Wilson Therapeutics, BioArctic, Bonesupport, PledPharma , Alligator Biosciences, Hansa Medical, Recipharm et al

      Hans-Peter Ostler

      Ledamot

      Född 1971. Har studerat Ekonomi och Juridik vid Handelshögskolan och vid Förvaltningshögskolan, Göteborgs Universitet.

      Styrelseledamot: Föreslagen ledamot i Promore Pharma Ab, Ledamot i S.P. HMSO Göteborg Ab, Föreslagen Vice Ordf. i Alligator Bioscience Ab.

      Aktieinnehav i Oblique Therapeutics Ab: 217 115 aktier via bolag och närstående.

      Huvudsaklig arbetslivserfarenhet: Hans-Peter har +20 års erfarenhet av Investment Banking, Private Banking och Asset Management. Hans-Peter har innehaft ledande befattningar hos Swedbank Markets, UBS AG, Danske bank och Söderberg&Partners. Hans-Peter har engagerats som styrelseledamot i Svenska och internationella företag inom Finans och Life Science så som Ancoria Insurance Public Ltd och Irlab Therapuetics Ab.

      Oberoende: Med beaktande av de krav som Svensk Kod för Bolagsstyrning uppställer avseende styrelsens oberoende är det valberedningens uppfattning att Hans-Peter Ostler är oberoende i förhållande till bolaget, dess ledning och större aktieägare.

      Stefan Ståhl

      Member of the board

      Born 1961. Professor of Molecular Biotechnology, PhD in Biotechnology, Master of Science in Chemical Engineering, Royal Institute of Technology, Stockholm

      Board member of Oblique Therapeutics Ab: member since 2021

      Chairman of the Board: Royal Institute of Technology Holding Ab, Amylonix Ab

      Board member: Intervacc Ab
      Member: The Human Protein Atlas Foundation
      Shareholding in Oblique Therapeutics Ab: no shares
      Main work experience: Professor of molecular biotechnology, dean of KTH biotechnology and founder of several companies in biotechnology, such as Creative Peptides Ab, Affibody Ab, Atlas Therapeutics and Amylonix Ab

      Camilla Svensson

      Member of the board

      Born 1973. Professor of Cellular and Molecular Pain Physiology, Karolinska Institutet, Ph.D in Molecular Pathology, UC San Diego, M.Sc in Pharmaceutical Biosciences, Uppsala University.

      Board member of Oblique Therapeutics AB: member since 2021.
      Member: Scandinavian Association for the Study of Pain, Stiftelsen Vectis.
      Shareholding in Oblique Therapeutics Ab: no shares.
      Main work experience: Professor of cellular and molecular pain physiology, research group leader and management team member at the Department of Physiology and Pharmacology, Karolinska Institutet. Member and chairman of the Swedish Young Academy. Scientific advisor and speaker for Cellectricon, Eli Lilly, BMS, Pfizer and others

      Pernilla Wittung-Stafshede

      Member of the board

      Born 1968. Professor of Chemical Biology, PhD in Physical Chemistry CTH, Master of Science in Chemical Engineering, Chalmers University of Technology Gothenburg.

      Board member of Oblique Therapeutics Ab: member since 2021
      Member: Royal Swedish Academy of Sciences (KVA), Royal Swedish Academy of Engineering Sciences (IVA)
      Shareholding in Oblique Therapeutics Ab: no shares
      Main work experience: Since Ph D 1996, worked 12 years in the USA at the California Institute of Technology, Tulane University, and Rice University, in the last 8 years as a professor at Umeå University and from 2015 professor at Chalmers. Scientific expertise and experimental research on the biophysics of proteins with a focus today on proteins in cancer and neurodegeneration. Published over 250 scientific articles. A number of international and national assignments over the years, such as the Biophysical Society's board, KAW, VR (NT Council 2010-2012). Leads Genie, a major gender equality initiative, at Chalmers since 2019. Member of KVA, IVA and the Nobel Prize Committee for Chemistry. Advisor to the Nobel Museum and scientific advisor Axial Therapeutics

      Management

      Carolina Trkulja, Ph.D.

      Founder and Chief Scientific Officer (CSO)

      Dr. Trkulja received a Ph.D. in biochemistry from Chalmers University of Technology in Gothenburg, Sweden. In her role, she is responsible for proteomics and pharmacology combined with her solid experience in research and development of antibodies. She has published her research in several top-tier scientific journals.

      Göran Gannedahl, M.D. Ph.D.

      Chief Medical Officer (CMO)

      Dr. Gannedahl has a long experience from the medical and pharmaceutical industry within the functions medical affairs, clinical research and business development. Combined with his expertise in oncology, translational medicine as well as the U.S. Food and Drug Administration and the needed requirements of drug development such as Good Laboratory Practice (GLP) certification, gives him an edge in the field. He is a medical doctor from Karolinska Institute, has a Ph.D. in Medicine from Uppsala University and has held positions as Global Head of Science Operations at Novartis, VP of R&D in Medical Affairs at Pronova Biopharma, and Executive Global Medical Affairs Leader at AstraZeneca.

      Sreesha P Srinivasa, Ph.D.

      Chief Development Officer (CDO)

      Dr. Srinivasa has more than 20 years of experience in global biopharma majors. He has broad experience in drug discovery and development with special focus on translational sciences. He has led and contributed to several discovery and development programs which have gone onto clinical development including FDA approved drugs Crizotinib and Palbociclib. During a 20+ years career in biopharma, Sreesh has held leadership positions of increasing responsibilities at Gilead, Pfizer, Jubilant, Piramal and Biocon. Prior to joining Oblique, Sreesh was Vice President & Head of Novel Biologics at Biocon Ltd. He holds a Ph.D. in Molecular Biology & Biochemistry from Washington University School of Medicine, St. Louis, USA and an M.Sc. in Molecular Biology and Biotechnology from Indian Agricultural Research Institute, New Delhi, India.

      Mats Jonasson

      Chief Financial Officer (CFO)

      Mats Jonasson has more than 30 years of experience working with entrepreneur-driven development companies. He has served as CFO in several organizations, especially in Sweden but also abroad. Mats has also worked as a consultant within accounting, auditing and tax matters. He has been co-founder and co-owner of several companies over the years. Mats has a degree in small business economy from the Gothenburg School of Business, Economics and Law.

      Marie Scherlund, Ph.D.

      Chief Program Officer (CPO)

      Dr. Scherlund has extensive experience from the life science industry, from early development to product launch, working at both large and small size companies such as Astra Zeneca, RISE, APL, Moberg Pharma and Cadila Pharmaceuticals. Scherlund holds a Ph.D in Pharmaceutics from Uppsala University, and has wide-ranging leadership experience from different senior management positions, amongst project leadership, regulatory affairs as well as heading departments of pharmaceutical development and quality control.

      Kjell Andersson, Ph.D. Med. Chemistry

      Head of Medicinal Chemistry

      Dr. Andersson has a background in medicinal chemistry, synthetic organic chemistry, drug discovery and drug development and is particularly knowledgeable in cardiovascular-gastrointestinal diseases and central nervous system (CNS). He is currently a chemistry consultant and founder of KemiKAN. Prior to this, he has held various executive positions within drug discovery such as acting Head of Medicinal Chemistry at AstraZeneca Mölndal but is also the inventor of the drugs Tesaglitazar (GALIDA) and Clevidipine (CLEVIPREX). Dr. Andersson holds a Ph.D. in Physical Organic Chemistry from the University of Gothenburg, Sweden.

      Cecilia Larsson, MBA

      Investor Relations Manager (IRM)

      “I’m an enthusiastic and performance driven person with a passion for business ideas which can provide sustainable improvements in modern society. With an inventor background I am motivated by creativity. I enjoy challenging conventional practices and continuously seek innovative solutions that can help people and society move forward.”
      Cecilia assumes the position as IRM-Investor Relation Manager at the Gothenburg office. Cecilia will be responsible for the procurement of potential new investors, as well as relationship with our current ones. Cecilia´s previous experience includes Recruitment Manager and Business Relationship and IPR Chef plus entrepreneurial innovation projects. Her multidisciplinary qualification has high compatibility with the future needs of Oblique Therapeutics. On her free time Cecilia enjoys running and spending time with her family and friends

      Mats Lindskog Ph.D.

      Chief Business Officer (CBO)

      Mats Lindskog joins Oblique Therapeutics as CBO- Chief Business Officer in Stockholm Office. In his role, Mats will be responsible for business development initiatives to secure overall company growth and to build and strengthen business relations with current and new partners.
      Mats has extensive knowledge and experience in areas that will be pivotal in his role at Oblique: Business development, pharmaceutical sales, and antibody technology.

      He holds a Master of Science in biotechnology and a PhD within Antibody-based proteomics, both from the Royal Institute of Technology (KTH) in Stockholm. Following his studies Mats worked at start-up biotech companies within antibody production and protein-protein interaction studies and within pharmaceutical Sales and Marketing, specifically within Oncology.
      Mats has since then held various executive positions at pharma companies within Business Unit Leadership, Strategy & Operations, Business Excellence and Commercial Operations.

      Scientific Advisory Board

      Kjell Andersson, Ph.D. Med. Chemistry

      Head of Medicinal Chemistry

      Dr. Andersson has a background in medicinal chemistry, synthetic organic chemistry, drug discovery and drug development and is particularly knowledgeable in cardiovascular-gastrointestinal diseases and central nervous system (CNS). He is currently a chemistry consultant and founder of KemiKAN. Prior to this, he has held various executive positions within drug discovery such as acting Head of Medicinal Chemistry at AstraZeneca Mölndal but is also the inventor of the drugs Tesaglitazar (GALIDA) and Clevidipine (CLEVIPREX). Dr. Andersson holds a Ph.D. in Physical Organic Chemistry from the University of Gothenburg, Sweden.

      Prof. Elias Arnér, M.D. Ph.D.

      Preclinical R&D Advisor

      Prof. Arnér is a professor in biochemistry, focusing on redox biology and cancer research at the Department of medical biochemistry and biophysics (MBB), Karolinska Institute in Stockholm, Sweden. In addition to being considered a world authority of redox enzymology Prof. Arnér is also highly involved in education. He received his Ph.D. in medicine and medical degree from the Karolinska Institute, and a post-doctoral degree from Ludwig Maximilian University of München, Germany. He has also been an invited lecturer and chair in several conferences, and serves as an editorial board member of prominent journals such as JBC and BBA.

      Prof. Rolf Karlsten, M.D.

      Clinical Pain Advisor

      Prof. Karlsten is currently the Head of the Multidisciplinary Pain Centre and Rehabilitation Medicine at Uppsala University Hospital, Sweden. He has a broad experience in pain research and management, medical in-licensing, R&D and projects in clinical development. Previously, he has held positions such as Medical Science Director at AstraZeneca, Senior Consultant at Uppsala University Hospital, and has worked with KOL networks in Europe, the U.S. and Japan. His background of studies includes M.D. and a Ph.D. in Medical Science from Uppsala University, Sweden, and a diploma in Pharmaceutical Medicine from the Karolinska Institute in Stockholm, Sweden.